Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOI9EL)

Drug Name

Radezolid Drug Info

Synonyms

Radezolid; Radezolid hydrochloride; RX-103; RX-1741; RX-01-667; Oxazolidinone antibiotic (bacterial infection), Rib-X Pharmaceuticals; Oxazolidinone antibiotic (CAP/uSSSI), Rib-X Pharamceuticals; Radezolid (iv, gram positive bacterial infection), Rib-X Pharmaceuticals; RX-1741 (iv, gram positive bacterial infection), Rib-X Pharmaceuticals; Radezolid (oral, CAP/uSSSI), Rib-X Pharmaceuticals; RX-1741 (oral, CAP/uSSSI), Rib-X Pharmaceuticals

Indication

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Phase 2	[1]
Pneumonia	CA40	Phase 2	[2]

Cross-matching ID

PubChem CID: 11224409
TTD Drug ID: DMOI9EL

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Bacterial Protein synthesis (Bact PROS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BC-3781 intravenous	DMY1UGV	Bacterial infection	1A00-1C4Z	Phase 2	[4]
Sutezolid	DM2KQ71	Tuberculosis	1B10-1B1Z	Phase 2	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Protein synthesis (Bact PROS)	TT2VX74	NOUNIPROTAC	Inhibitor	[3]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT00640926) Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia. U.S. National Institutes of Health.
3	Antibiotics in the clinical pipeline in 2011. J Antibiot (Tokyo). 2011 Jun;64(6):413-25.
4	Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Antimicrob Agents Chemother. 2013 Sep;57(9):4489-95.
5	Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila. Antimicrob Agents Chemother. 2010 Jun;54(6):2549-59.